NT5E and melanoma: In addition, CD73 may serve as a target to be combined with other immunotherapies, which has been reported in pre-clinical models in other cancer types (56, 57), supporting that combination therapy of CD73 inhibition and current melanoma immunotherapies is worth exploring.